A pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core including crystalline L-menthol dissolved in a terpene-based essential oil. A proteinaceous coating of a continuous film of proteinaceous material is over the core.

A method of making an L-menthol dosage form includes forming a wet granulation including an L-menthol source and at least one pharmaceutical excipient. The wet granulation is extruded into an extrudate and the extrudate is cut into individual core pieces. The individual core pieces are spheronized into individual spheronized cores and the individual spheronized cores are dried to form dried individual spheronized cores. The dried individual spheronized cores are spray coated with a liquid proteinaceous material that forms a film of a proteinaceous material over the dried individual spheronized cores. The film of proteinaceous material is dried over the dried individual spheronized cores to form individual subcoated cores. An enteric coating is applied and dried over the individual subcoated cores to form a plurality of individual enteric coated cores.

The present invention relates to a solid dosage form comprising two or more compounds selected from N,N-dimethyltryptamine and its deuterated analogues and pharmaceutically acceptable salts thereof, and methods of treatment (e.g., of a psychiatric disorder or a neurological disorder) comprising administering the solid dosage form to a patient in need thereof.

This invention provides compositions comprising a protein and an omega-3 fatty acid, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.

A stimulus-responsive carrier, a method for making and a method of using the same are disclosed. The stimulus-responsive carrier comprises a polymeric component comprising poly(N-isopropylacrylamide) (PNIPAM), a copolymer comprising units derived from N-isopropylacrylamide and acrylic acid (PNIPAM-AA), poly N-vinylpyrrolidone, a copolymer of N-isopropylacrylamide and hydroxymethylacrylamide (PNIPAM-HMAAm), a copolymer of N-isopropylacrylamide and allylamine (poly(NIPAAM-co-allylamine)), poly 2-(2-methoxyethoxy) ethyl methacrylate, or any combination thereof; and a second component disposed within the polymeric component, the second component comprising a hydrogel, wherein the second component has a different composition than the polymeric component. The stimulus-responsive carrier is responsive to a stimulus comprising a temperature change, a pH change, application of a magnetic field, or any combination thereof.

The invention relates to a delivery device formed by an aggregation of a plurality of individual particles in a host fluid, wherein one or more individual particles of the plurality of individual particles has a density of less than the host fluid, preferably less than water, and a bonding property which permits the initially separate individual particles to aggregate in said host fluid, i.e. to be connected one to another in said host fluid, to form the aggregation. The invention further relates to a method for producing a plurality of individual particles and to a method of forming a delivery device from a plurality of particles in a host fluid at an aggregation site.

A composition comprising a core material, having a taste value and a polymeric coating. The polymeric coating substantially surrounds the core material and comprises a cationic polymer and optionally an anionic polymer. The polymeric coating has a uniform thickness ranging from 2 μm to 20 μm. The composition provides release of a portion of the core material which is taste masked over a time period ranging from 0.5 minute to 2 minutes in the oral cavity and provides a modified-release of the remaining core material in a gastrointestinal tract.

The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

The present disclosure relates to a microcarrier for embolization, and a preparation method therefor, wherein the microcarrier comprises a biodegradable porous polymer, a stimulus-responsive polymer captured in the biodegradable porous polymer, and drug-supported magnetic nanoparticles captured in the stimulus-responsive polymer, thereby being capable of operating in an in vivo tumor-targeting manner and releasing, by an external stimulus, the drug-supported nanoparticles, so as to be effectively usable in tumor embolization.

A composition comprising a core material, having a taste value and polymeric coating. The polymeric coating substantially surrounds the core material and comprises a cationic polymer and optionally an anionic polymer. The polymeric coating has a uniform thickness ranging from 2 μm to 20 μm. The composition provides release of a portion of the core material which is taste masked over a time period ranging from 0.5 minute to 2 minutes in the oral cavity and provides a modified-release of the remaining core material in a gastrointestinal tract.